Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-16
2010-06-01
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C549S327000, C549S328000, C549S329000
Reexamination Certificate
active
07728153
ABSTRACT:
The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.
REFERENCES:
patent: 4598089 (1986-07-01), Haduary et al.
patent: 4806564 (1989-02-01), Chabala et al.
patent: 4873260 (1989-10-01), Alberts et al.
patent: 4931463 (1990-06-01), Barbier et al.
patent: 4983746 (1991-01-01), Barbier et al.
patent: 5175186 (1992-12-01), Barbier et al.
patent: 5246960 (1993-09-01), Barbier et al.
patent: 5260310 (1993-11-01), Derungs et al.
patent: 5376674 (1994-12-01), Derungs et al.
patent: 5399720 (1995-03-01), Karpf et al.
patent: 5466708 (1995-11-01), Derungs et al.
patent: 5981771 (1999-11-01), Okeda et al.
patent: 185359 (1991-12-01), None
patent: 03115274 (1991-05-01), None
patent: WO 00/04300 (2000-01-01), None
Tomoda et al. Journal of Organic Chemistry, 1997, 62, 2161-2165.
Purohit et al. Journal of Organic Chemistry, 2006, 71, 4549-4558.
Sauer, Journal of American Chemical Society, 1947, 69(10) 2444-2448.
Calter, Journal of Organic Chemistry, 1996, 61, 8006.
Liu et al. “Activity-based protein profiling: the serine hydrolases.” Proc. Natl. Acad. Sci. U.S.A 96:14694-9, 1999.
Umezawa et al. “Ebelactone, an inhibitor of esterase, produced by actinomycetes.” J. Antibiot. (Tokyo). 33:1594-1596, 1980.
Uotani et al. “Structural studies on ebelactone A and B, esterase inhibitors produced by actinomycetes.” J. Antibiot. (Tokyo). 35:1495-1499, 1982.
McNeely and Benfield, “Orlistat.” Drugs 56:241-9; discussion 250, 1998.
Auerbach, W. and Auerbach, R. “Angiogenesis inhibition: a review.” Pharmacol. Ther. 63:265-311, 1994.
Folkman, J. “Angiogenesis in cancer, vascular, rheumatoid and other disease.” Nat. Med. 1:27-31, 1995.
Creamer, J. D. And Barker, J. N. “Vascular proliferation and angiogenic factors in psoriasis.” Clin. Exp. Dermatol. 20:6-9, 1995.
Kuhajda et al. “Synthesis and antitumor activity of an inhibitor of fatty acid synthase.” Proc. Natl. Acad. Sci. U.S.A. 97:3450-3454, 2000.
Paterson and Hulme, “Total Synthesis of (-)-Ebelactone A and B” J. Org. Chem., 1995, 60(11),3288-3300.
Remington: The Science and Practice of Pharmacy (19th ed.) ed., 29-31, 1995.
Salcedo et al. “Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression.” Blood 96:34, 40, 2000.
Price et al. “Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.” Cancer Res. 50:717-721, 1990.
Greenbaum et al. “Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools” Chem. Biol. 7:569-81, 2000.
Patricelli et al. “Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes.” Proteomics 1:1067-1071, 2001.
Hadvary et al. “The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase.” J. Biol. Chem. 266:2021-7, 1991.
Liu et al., supra; and Kidd et al. “Profiling Serine Hydrolase Activities in Complex Proteomes.” Biochemistry 40:4005-4015, 2001.
Kuhajda et al. “Fatty acid synthesis: a potential selective target for antineoplastic therapy.” Proc. Nat. Acad. Sci. U.S.A. 91:6379-83, 1994.
Pizer et al. “Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines.” Cancer Res. 58:4611-5, 1998.
Kidd et al. “Profiling Serine Hydrolase Activities in Complex Proteomes.” Biochemistry 40:4005-4015, 2001.
Landry et al. “A Method for Application of Samples to Matrix-Assisted Laser Desorption Ionization Time-of-Flight Targets . . . ” Anal. Biochem. 279:1-8, 2000.
Harvey et al. “Insights into a plasma membrane signature.” Physiol. Genomics. 5:129-136, 2001.
Kurebayashi et al. “Quantitative demonstration of spontaneous metastasis of MCF-7 human breast cancer cells . . . ” Cancer Res. 53:2178-2187, 1993.
Shafie et al. “Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice.” Cancer Lett. 11:81-87, 1980.
Axelrod Fumiko
Kridel Steven J.
Ma Gil
Purohit Vikram
Romo Daniel
Catalyst Law Group APC
Chandrakumar Nizal S
Seaman D. Margaret
The Burnham Institute for Medical Research
LandOfFree
Method for the asymmetric synthesis of beta-lactone compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the asymmetric synthesis of beta-lactone compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the asymmetric synthesis of beta-lactone compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4194874